



Dkt. 96700/341

METHOD FOR DETECTING HEMOLYSIS

Background of the Invention

5 Anemia is a reduction in the normal levels of erythrocytes per cubic millimeter, the quantity of hemoglobin, or in the volume of packed red cells per one hundred milliliters. Although anemia is not a specific disease, it is the principal manifestation of a number of  
10 abnormal conditions such as deficiency conditions (caused by lack of iron, vitamin B12, or folic acid), hereditary disorders of the erythrocyte, disorders of the hematopoietic tissues (bone marrow damage or a hyperactive spleen) and gastrointestinal tract bleeding as a result of  
15 cancer or hemorrhage associated with organ trauma. As such, the diagnosis of the etiology of a patient's anemia is of great importance in enabling a treating physician to choose an appropriate therapeutic regimen.

Hemolysis is the disruption of the erythrocyte  
20 membrane causing release of hemoglobin and is one of the main causes of anemia. Hemolysis can occur as a result of a variety of factors, e.g. intracorpuseular hereditary defects within the erythrocyte triggered by extracellular factors such as drugs, plasma components, or splenic  
25 hyperactivity; or extracorpuseular factors such as infection, immunologic disease, and chemical or physical agents.

Anemia due to hemolysis is currently diagnosed by examination of a number of indirect markers. Findings  
30 of reticulocytosis (due to the increased efforts of the bone marrow to compensate for excessive erythrocyte destruction), increased erythrocyte fragility, shortened erythrocyte life span, hyperbilirubinemia, elevated serum levels of lactate dehydrogenase, increased fecal and  
35 urinary urobilinogen, or hemoglobinemia in cases of massive intravascular hemolysis, for example, will result in a diagnosis of hemolysis. However, use of such indirect indicators in the diagnosis of hemolysis is inaccurate. Very often, in patients who are suspected of

suffering from hemolysis, the levels of the indirect markers are already altered as a result of concomitant disease. As a result, patient care is adversely affected because his or her therapy might be initiated or changed  
5 based upon misdiagnosis. Accordingly, there exists a need for an accurate and specific means for diagnosing hemolysis.

Adenylate kinases are a large family of enzymes found in plants, bacteria, and animals. The different  
10 members of the adenylate kinase family differ in composition, thermostability, optimum pH, substrate specificities, and kinetics. In humans, a variety of adenylate kinase isoenzymes, from a number of distinct sources, such as liver, intestine, muscle and  
15 erythrocytes, can be found in serum.

The inventors of the present invention have discovered that the level of erythrocyte adenylate kinase in serum correlates with the degree of hemolysis of blood. Based upon this discovery, the inventors of the present  
20 invention have devised an accurate method for detecting hemolysis in blood. Accordingly, the present invention satisfies the need for an accurate means for diagnosing hemolysis.

#### 25                   Summary of the Invention

The present invention provides a method for detecting the presence of hemolyzed erythrocytes in blood comprising detecting erythrocyte adenylate kinase in a serum sample of said blood.

30                   The present invention also provides a method for diagnosing a hemolytic condition in a subject suspected of having a hemolytic condition comprising collecting a serum sample from said subject, and detecting erythrocyte adenylate kinase in said serum sample.

35                   Lastly, the present invention provides a method of monitoring the level of hemolysis in a patient which comprises measuring the erythrocyte adenylate kinase

activity in a serum sample obtained from a patient being treated for hemolysis.

#### Brief Description of the Figures

5                Figure 1 represents a plot of adenylate kinase activity versus serial dilutions of a hemolyzed serum sample which exhibited high adenylate kinase activity. The serum sample was diluted using a solution of 9 g/L sodium chloride and the diluted solutions were assayed for adenylate kinase activity using a Cobas-~~fara~~<sup>FARA</sup> centrifugal analyzer.

10              Figure 2 represents a scan of adenylate kinase isoenzyme activities after electrophoretic resolution of a hemolyzed serum sample (2g/L hemoglobin) containing 87 U/L of adenylate kinase activity. The serum sample was subjected to adenylate kinase isoenzyme electrophoretic fractionation on an agarose gel with the Helena REP system. The direction of migration is from left to right (anode is to the right). The slow moving fluorescent band  
15              migrating near the cathode represents erythrocyte adenylate kinase isoenzyme activity.

20              Figure 3 represents a plot of erythrocyte adenylate kinase activity versus hemoglobin concentration in hemolyzed samples. Erythrocyte adenylate kinase activity (U/L) was calculated by multiplying total adenylate kinase in each sample (determined using the Cobas-~~fara~~<sup>FARA</sup> centrifugal analyzer) by the percentage erythrocyte adenylate kinase (determined from the REP electrophoresis assay) in the sample. The same samples  
25              were also assayed for hemoglobin concentration with the Coulter STKS analyzer. Results are of duplicate assays.


#### Detailed Description of the Invention

30              The present invention provides a method for detecting the presence of hemolyzed erythrocytes in blood which comprises detecting erythrocyte adenylate kinase in a serum sample of the blood. The method of the present

invention may be used to detect hemolysis in a subject suspected of having hemolysis. The subject may be animal or human, and preferably is human. The serum sample may be obtained by methods known in the art such as removal of blood by venipuncture followed by clotting (to remove fibrinogen) and slow speed centrifugation (2500g) to remove particulate and cellular material followed by separation of the supernatant (serum) from the particulate and cellular material.

In one embodiment of the present invention, the erythrocyte adenylate kinase is detected by loading the serum sample onto an agarose gel of the type used to separate creatine kinase isoenzymes and electrophoresing the serum sample through the matrix of the gel. The erythrocyte adenylate kinase present in the serum sample migrates to a location on the gel matrix which corresponds to the MM isoenzyme of creatine kinase (Murthy, V.V. Journal of Clinical Laboratory Analysis 8:140-143 (1994)).

Upon completion of electrophoresis, the gel is submerged in an adenylate kinase-specific visualization reagent, preferably containing 12 mMol/L adenosine diphosphate, 60 mMol/L D-glucose, 6 mMol/L nicotinamide adenine dinucleotide, 9000 U/L hexokinase and 7500 U/L glucose-6-phosphate dehydrogenase. The combination of adenylate kinase in the gel and the adenylate kinase-specific visualization reagent initiates a coupled enzyme reaction which produces NADH (the reduced form of nicotinamide-adenine-dinucleotide) as an endproduct, as exemplified in the following reaction scheme:



The endproduct, NADH, emits fluorescence upon exposure to ultraviolet light. The erythrocyte adenylate kinase is detected by the emission of fluorescent light from the location on the gel matrix to which the erythrocyte  
5 adenylate kinase migrates.

In another embodiment of the present invention, the presence of erythrocyte adenylate kinase in a serum sample is detected by contacting the serum sample with antibody against erythrocyte adenylate kinase and then  
10 detecting the complex formed between the erythrocyte adenylate kinase present in the serum sample and the erythrocyte adenylate kinase-specific antibody. The erythrocyte adenylate kinase-specific antibody can be monoclonal or polyclonal.

The antibodies against erythrocyte adenylate kinase must be raised against purified protein. Purification of erythrocyte adenylate kinase may be accomplished by fractionating hemolysates with ammonium sulfate, and fractionating the erythrocyte adenylate  
15 kinase using ion exchange chromatography or sephadex size exclusion chromatography.

Erythrocyte adenylate kinase can be used to make antibodies by methods well known in the art. The polyclonal antibody can be produced by immunizing a  
25 rabbit, mouse, or rat with the purified protein. If necessary, the protein may be attached to a carrier molecule (such as bovine serum albumin or keyhole limpet hemocyanin) in order to increase immunogenicity. After administration of a booster injection 4-6 weeks after the  
30 primary injection and additional boosters administered at later periods, if required, the presence of antibody is detectable by a variety of methods such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA) or immunoprecipitation.

Monoclonal antibodies can be produced by  
35 removing the spleen from the immunized rabbit, mouse or rat and fusing the spleen cells with myeloma cells to form

a hybridoma. The hybridoma, when grown in culture, will produce a monoclonal antibody which can be detected and purified by RIA or ELISA.

In order to detect erythrocyte adenylate kinase  
5 by immunoprecipitation, a serum sample thought to contain erythrocyte adenylate kinase, is first mixed with antibody against erythrocyte adenylate kinase. The formation of a complex between antibody and erythrocyte adenylate kinase is then detected by sodium dodecyl sulfate (SDS)  
10 polyacrylamide electrophoresis (PAGE) (Davis, et.al., Basic Methods in Molecular Biology, 2nd. ed., (eds. Appleton & Lange), Section 17-2 (1994)).

The erythrocyte adenylate kinase in a serum sample may also be detected by Western blotting and  
15 immunodetection. A Western blot is prepared by the separation of the proteins in a serum sample thought to contain erythrocyte adenylate kinase by SDS PAGE; transferring the gel to a membrane (e.g. nitrocellulose); followed by incubating the membrane with primary antisera;  
20 and then detecting the presence of erythrocyte adenylate kinase using secondary antibody (Davis, et.al., supra).

In both immunoprecipitation, and Western blotting and immunodetection, detection of complexes between antibody and target can be accomplished by  
25 isotopic or nonisotopic means, i.e. the erythrocyte adenylate kinase antibody (immunoprecipitation) or secondary antiserum (Western blotting) can be labeled with a radioisotope such as radioactive iodine, and complex formation detected by autoradiography of the gel or  
30 membrane; alternatively, the erythrocyte adenylate kinase antibody or secondary antiserum can be labeled with nonisotopic means, e.g. it can be conjugated to horseradish peroxidase or alkaline phosphatase and complex formation detected by a visible color change and  
35 conventional autoradiography, respectively (Davis, et.al., supra).

Detection of erythrocyte adenylate kinase by immunoelectrophoresis can be accomplished by electrophoresing the serum sample through a gel matrix such as agarose and then placing erythrocyte adenylate kinase antibody in a trough which is cut parallel to the direction of electrophoresis. The antibodies are allowed to diffuse through the gel - the proteins diffusing radially from their electrophoretic placement and the antibodies diffusing perpendicularly from the trough. If erythrocyte adenylate kinase is present in the serum sample, it will be detected by the formation of an elliptical precipitin arc (Davis, et.al. Microbiology, 4th. ed., pp. 274-275 (1990)).

The present invention also provides a method for monitoring hemolysis in a subject being treated for an hemolysis-related condition such as hemolytic anemia, by measuring and quantifying the erythrocyte adenylate kinase activity in the serum sample. The method comprises the steps of first determining the total adenylate kinase activity in the serum sample; then calculating the percentage erythrocyte adenylate kinase in the sample; and finally calculating the total erythrocyte adenylate kinase activity in the sample by multiplying the value for percentage erythrocyte adenylate kinase by the value for total adenylate kinase activity.

Total adenylate kinase activity is determined by mixing the serum sample with an adenylate kinase-specific visualization reagent (described above) and then analyzing the mixture in a Cobas-<sup>FARA</sup>~~Fara~~ centrifugal analyzer (from Roche Diagnostics, Branchburg, New Jersey). Total adenylate kinase activity is calculated by measuring the formation of the NADH end product of the already described coupled enzyme reaction (formation of NADH is measured from the change in absorbance of the mixture over time). One unit of adenylate kinase is equal to one micromole of product (NADH) formed per minute.

The percentage of erythrocyte adenylate kinase in the serum sample is measured by electrophoresing the serum sample on an agarose gel of the type used to separate creatine kinase isoenzymes, staining the gel with an adenylate kinase-specific visualization reagent (described above) and irradiating the gel with ultraviolet light. Measurement of total fluorescence from the gel provides a value for the total amount of adenylate kinase present; measurement of fluorescence from the location of the gel at which erythrocyte adenylate kinase migrates, provides a value for the amount of erythrocyte adenylate kinase present in the serum sample. The percentage of erythrocyte adenylate kinase in the sample is calculated by dividing the value for erythrocyte adenylate kinase by the value for adenylate kinase. The erythrocyte adenylate kinase activity in the serum sample is calculated by multiplying the percentage of erythrocyte adenylate kinase by the adenylate kinase activity.

Alternatively, erythrocyte adenylate kinase activity can be quantitated using the monoclonal or polyclonal antibodies described above. In order to quantitate the activity of erythrocyte adenylate kinase present in a serum sample, RIA or ELISA can be used. Another suitable method involves immunoprecipitation in solution followed by measuring the development of turbidity using a turbidometer or nephelometer.

For RIA, a known concentration of radioactively labeled erythrocyte adenylate kinase is added to the serum sample together with antibody. The level of binding between antibody and labeled erythrocyte adenylate kinase is used as a measure of the activity of erythrocyte adenylate kinase present in the serum sample by reference to calibration curves prepared using purified erythrocyte adenylate kinase of known activity (Davis, et.al. Microbiology, 4th. ed., pp. 267-268 (1990)).

For ELISA, erythrocyte adenylate kinase antibody (antibody 1) is bound to a solid surface, e.g. plastic beads or tray. The bound antibody is then mixed with a serum sample thought to contain erythrocyte adenylate kinase. A second erythrocyte adenylate kinase antibody (antibody 2) is then added to the mixture. Antibodies 1 and 2 recognize different regions of the erythrocyte adenylate kinase molecule and so both can bind in a non-exclusive manner. A third antibody (antibody 3), which reacts with antibody 2, but not antibody 1 is then added. Antibody 3 is conjugated to an enzyme and it is the action of this enzyme which provides the basis for detection. A variety of enzymes can be used in ELISAs, e.g. alkaline phosphatase, horseradish peroxidase, or beta-galactosidase. No matter the enzyme used for detection, quantitation of erythrocyte adenylate kinase activity in the serum sample is measured both accurately and rapidly using calibrated, automated ELISA reader devices (Davis, et.al. Microbiology, 4th. ed., pp. 269-270 (1990)).

The present invention is described in the following Experimental Details section, which sets forth a specific example to aid in the understanding of the invention, and should not be construed to limit, in any way, the invention as defined in the claims which follow thereafter.

#### Experimental Details Section

##### A. Materials and Methods

##### 1. Electrophoresis

The Helena REP creatine kinase electrophoresis apparatus was used to fractionate the erythrocyte adenylate kinase in serum samples. Agarose gels used for fractionating creatine kinase in the REP creatine kinase system were purchased from Helena Laboratories, Beaumont, Texas. All other reagents were purchased from Sigma, St. Louis, Missouri.

## 2. Assays

The adenylate kinase specific visualization reagent used to visualize adenylate kinase on the gel contained: 12 mMol/L adenosine diphosphate, 60 mMol/L each  
5 of D-glucose and magnesium acetate, 6 mMol/L nicotinamide adenine dinucleotide, 9000 U/L of hexokinase and 7500 U/L of glucose-6-phosphate dehydrogenase in 100 mMol/L Tris buffer, pH 8.0. Adenylate kinase activity on the gel was visualized as a 360 nm fluorescence spot of the NADH  
10 product of the coupled enzyme reaction described above.

Total adenylate kinase activity in serum was measured using a Cobas-Fara centrifugal analyzer (from Roche Diagnostics, Branchburg, New Jersey) and a ten fold dilution of the adenylate kinase visualization reagent  
15 described above.

The relative percentage of erythrocyte adenylate kinase present in the serum sample was determined from the fluorescence associated with the known location of the erythrocyte adenylate kinase on the gel. The erythrocyte  
20 adenylate kinase activity was calculated by multiplying the percentage of erythrocyte adenylate kinase present in the serum sample by the total adenylate kinase activity.

The amount of hemolysis was estimated by measuring serum hemoglobin concentration using a Coulter  
25 STKS instrument (Coulter Corporation, Hialeah, Florida).

## 3. Serum Samples

Serum samples were obtained from 20 patients suspected of having hemolysis and analyzed. Fifteen out  
30 of the 20 samples exhibited various degrees of red pigmentation upon visual inspection. The remaining 5 samples did not show any obvious hemolysis.

Freshly collected blood from a volunteer was used to obtain an erythrocyte hemolysate. Serial  
35 dilutions of the hemolysate were made with a hypotonic solution containing sodium chloride prior to assaying the samples for adenylate kinase.

B. Results

The assay for total adenylate kinase was found to be linear up to 500 U/L, when a serially diluted freshly prepared erythrocyte hemolysate was used as the source of adenylate kinase (see Figure 1). The total adenylate kinase activity in the serum samples analyzed ranged from 5 to 464 U/L as shown in Table 1. Results from duplicate assays showed a high degree of reproducibility.

The serum samples with measurable total adenylate kinase activity were electrophoresed in the REP creatine kinase instrument using the agarose gels routinely employed for creatine kinase fractionation. Adenylate kinase was visualized using the adenylate kinase-specific visualization reagent. All 15 samples which exhibited hemolysis on visual inspection, showed elevated erythrocyte adenylate kinase activity. A representative scan of erythrocyte adenylate kinase activity is shown in Figure 2. Erythrocyte adenylate kinase activity was not detected in the 5 serum samples which were not hemolyzed on visual inspection.

The erythrocyte adenylate kinase activity, measured using the REP electrophoresis assay, was found to be linear between the ranges of 0-120 U/L and was proportional to hemoglobin concentrations between 0 and 5 g/L as shown in Figure 3. About 1 U/L erythrocyte adenylate kinase activity is equal to about 0.005 g/DL hemoglobin concentration.

All publications mentioned herein above are hereby incorporated in their entirety.

While the foregoing invention has been described in some detail for the purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of the disclosure that various changes in form and detail can be made without departing from the true scope of the invention in the appended claims.

Table 1

Effect of Hemolysis on Adenylate Kinase Activity in Serum

	SAMPLE NUMBER	HEMOGLOBIN (g/L)	ADENYLATE KINASE (U/L)	
			Run 1	Run 2
5	1	1.0	21	22
	2	1.0	48	48
	3	1.0	21	21
	4	2.0	45	44
10	5	2.0	48	48
	6	2.0	58	56
	7	2.0	53	53
	8	2.0	64	63
	9	2.0	88	86
15	10	2.0	157	150
	11	3.0	82	85
	12	3.0	172	165
	13	5.0	153	147
	14	5.0	472	454
20	15	6.0	194	187
	16	0	1	0*
	17	0	5	5*
	18	0	5	5*
	19	0	11	11*
25	20	0	32	32*

\* Samples 1-15 were hemolyzed; samples 16-20 were not.

What is Claimed is:

1. A method for detecting the presence of hemolyzed erythrocytes in blood comprising detecting erythrocyte adenylate kinase in a serum sample from said blood.

2. The method of Claim 1, wherein said erythrocyte adenylate kinase, if present, is detected by the steps of:

(a) electrophoresing said serum sample in a gel matrix;

(b) contacting said gel matrix with an adenylate kinase-specific visualization reagent;

(c) exposing said gel matrix to ultraviolet light; and

(d) detecting said erythrocyte adenylate kinase.

3. The method of Claim 2, wherein said adenylate kinase visualization reagent comprises adenosine diphosphate, D-glucose, nicotinamide adenine dinucleotide, hexokinase and glucose-6-phosphate dehydrogenase.

4. The method of Claim 1, wherein said erythrocyte adenylate kinase is detected by contacting said serum sample with an antibody which specifically binds to erythrocyte adenylate kinase, and detecting the formation of a complex between said erythrocyte adenylate kinase and said antibody.

5. The method of Claim 4, wherein said contacting is effected by immunoprecipitation.

6. The method of Claim 4, wherein said contacting is effected by Western transfer blotting and immunodetection.

7. The method of Claim 4, wherein said contacting is effected by immunoelectrophoresis.

8. The method of Claim 4, wherein said detecting is effected by isotopic means.

9. The method of Claim 4, wherein said detecting is effected by nonisotopic means.

10. The method of Claim 4, wherein said antibody is polyclonal or monoclonal.

11. A method for diagnosing a hemolytic condition in a subject suspected of having a hemolytic condition comprising collecting a serum sample from said subject, and detecting erythrocyte adenylate kinase in said serum sample.

12. A method of monitoring the level of hemolysis in a subject being treated for hemolysis comprising collecting a serum sample from said subject, and measuring erythrocyte adenylate kinase activity in said serum sample.

13. The method of Claim 12, wherein said erythrocyte adenylate kinase is measured by the steps of:

(a) determining the total adenylate kinase activity in said serum sample;

(b) calculating the percentage of erythrocyte adenylate kinase to said total adenylate kinase in said serum sample; and

(c) multiplying said percentage of erythrocyte adenylate kinase by said total adenylate kinase activity.

14. The method of Claim 13, wherein said total adenylate kinase activity is determined by mixing said serum sample with an adenylate kinase-specific visualization reagent and measuring absorbance of the mixture.

15. The method of Claim 13, wherein said percentage of erythrocyte adenylate kinase to said total adenylate kinase is determined by:

(a) electrophoresing said serum sample in a gel matrix so that said erythrocyte adenylate kinase migrates on said gel matrix;

(b) contacting said gel matrix with an adenylate kinase-specific visualization reagent;

(c) exposing said gel matrix to ultra-violet light;

(d) determining the level of total adenylate kinase by measuring total fluorescent light emitted from said gel matrix;

5 (e) determining the level of erythrocyte adenylate kinase by measuring fluorescent light emitted from said gel matrix corresponding to said erythrocyte adenylate kinase migration; and

10 (f) calculating said percentage of erythrocyte adenylate kinase to said total adenylate kinase by dividing said level of erythrocyte adenylate kinase by said level of total adenylate kinase.

15 16. The method of Claim 12, wherein said erythrocyte adenylate kinase activity is determined by contacting said serum sample with an antibody which specifically binds to erythrocyte adenylate kinase, and calculating the activity of said erythrocyte adenylate kinase present in said serum sample by measuring antibody binding.

20 17. The method of Claim 16, which is effected by an enzyme-linked immunosorbent assay.

18. The method of Claim 16, which is effected by a radioimmunoassay.

add  
B2

add  
C2

SECRET - SECURITY

**METHOD FOR DETECTING HEMOLYSIS**

**ABSTRACT OF DISCLOSURE**

This invention provides a method for determining the presence of hemolyzed erythrocytes in blood by  
5 detecting erythrocyte adenylate kinase in a serum sample from the blood. This invention also provides a method for diagnosing a hemolytic condition in a subject suspected to be suffering from hemolysis, as well as a method for monitoring hemolysis in a subject undergoing treatment for  
10 a hemolytic condition.

1/3  
Figure 1

Linearity of Adenylate Kinase






Figure 2



3/3  
FIGURE 3

08/421079





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Vadiraja Murthy  
Edward R. Burns

Serial: To Be Assigned

Filed: Filed Herewith

For: Method For Detecting Hemolysis

STATEMENT PURSUANT TO 37 C.R.F. § 1.27

The undersigned hereby declares that:

1. I am the Associate Dean for Business Affairs of Yeshiva University and have authority to act on behalf of Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University.

2. Albert Einstein College of Medicine of Yeshiva University qualifies as a non-profit organization as defined in 37 C.F.R. 1.9(e)(1).


3. All right, title and interest in and to the above-identified invention has been assigned to and remains with Albert Einstein College of Medicine of Yeshiva University.

The undersigned further declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

YESHIVA UNIVERSITY THROUGH ITS  
ALBERT EINSTEIN COLLEGE OF  
MEDICINE

Date: \_\_\_\_\_

3/29/95

  
Emanuel Genn  
Associate Dean for Business  
Affairs of Albert Einstein  
College of Medicine of Yeshiva  
University, a Division of  
Yeshiva University

## DECLARATION

POWER OF ATTORNEY FOR PATENT APPLICATION  
ENGLISH LANGUAGE DECLARATION

## APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**METHOD FOR DETECTING HEMOLYSIS**

the specification of which  
(check one)

☒ is attached hereto

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**PRIOR FOREIGN APPLICATION(S)**

NUMBER	COUNTRY	(DAY/MONTH/YEAR FILED)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56 (a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS PATENTED, PENDING, ABANDONED

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Morton Amster, Registration No. 16,877  
Jesse Rothstein, Registration No. 20,118  
Daniel S. Ebenstein, Registration No. 24,932  
Philip H. Gottfried, Registration No. 25,871  
Michael J. Berger, Registration No. 25,829

Neil M. Zipkin, Registration No. 27,476  
Anthony F. LoCicero, Registration No. 29,403  
Joel E. Lutzker, Registration No. 29,406  
Kenneth P. George, Registration No. 30,259  
Craig J. Arnold, Re. No. 34,287

SEND CORRESPONDENCE TO:

**AMSTER, ROTHSTEIN & EBENSTEIN**  
90 Park Avenue, New York, New York 10016

DIRECT TELEPHONE CALLS TO: (NAME AND TELEPHONE NUMBER)

**Craig J. Arnold (212) 697-5995**

FULL NAME OF SOLE OR FIRST INVENTOR

**Vadiraja Murthy**

INVENTOR'S SIGNATURE

*Vadiraja V. Murthy*

RESIDENCE

**100 Lindbergh Boulevard, Teaneck, New Jersey 07666-5347**

POST OFFICE ADDRESS

**same as residence address**

FULL NAME OF SECOND JOINT INVENTOR, IF ANY

**Edward R. Burns**

SECOND INVENTOR'S SIGNATURE

*Edward R. Burns*

RESIDENCE

**70-45 173rd Street, Fresh Meadow, New York 11365**

POST OFFICE ADDRESS

**same as residence address**

FULL NAME OF THIRD JOINT INVENTOR, IF ANY

INVENTOR'S SIGNATURE

RESIDENCE

POST OFFICE ADDRESS

CITIZENSHIP

**USA**

DATE

**4/6/95**

CITIZENSHIP

**USA**

DATE

**4/6/95**

3/3  
FIGURE 3

08/421079

